GC
NAMS icon

Guggenheim Capital’s NewAmsterdam Pharma NAMS Stock Holding History

Guggenheim Capital’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$217K Sell
6,400
-58
-0.9% -$1.91K ﹤0.01% 1628
2026
Q1 		$207K Buy
6,458
+70
+1% +$2.28K ﹤0.01% 1514
2025
Q4 		$224K Buy
+6,388
New +$232K ﹤0.01% 1648

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

Guggenheim Capital's NAMS Position: Q2 2026 in Review

Guggenheim Capital reduced its NewAmsterdam Pharma (NAMS) stake by 0.9% in Q2 2026, selling an estimated $1.91K and leaving 6,400 shares worth $217K. The position accounts for ﹤0.01% of the portfolio, ranked #1628.

Guggenheim Capital first reported a position in NAMS in Q4 2025 and has held it in 3 quarters since. The position peaked at $224K in Q4 2025. 195 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

  • Guggenheim Capital held 6,400 shares of NewAmsterdam Pharma worth $217K as of Q2 2026.
  • Guggenheim Capital sold 58 NewAmsterdam Pharma shares in Q2 2026, an estimated $1.91K.
  • NewAmsterdam Pharma made up ﹤0.01% of Guggenheim Capital's portfolio in Q2 2026, its #1628 holding.
  • Guggenheim Capital first reported a position in NewAmsterdam Pharma in Q4 2025 and has held it in 3 quarters since.
  • Guggenheim Capital's NewAmsterdam Pharma position peaked at $224K in Q4 2025.
  • 195 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on Guggenheim Capital's 13F filing for Q2 2026, filed 12 Aug 2026.